HC Wainwright & Co. Reiterates Buy on Edap TMS, Maintains $10 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:FOCL) with a Buy and maintains $10 price target.
Stocks · News reference
FocalTherics Launches First European Commercial Endometriosis Focal One Program With Treatment Of Initial Patients In Toulouse, France
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — EDAP TMS SA (FOCL)
Filed: 2026-08-19 AccNo: 0001104659-26-098487 Size: 212 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Edap TMS Q2 2026 Earnings Call: Complete Transcript
Edap TMS (NASDAQ:FOCL) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
FocalTherics Q2 EPS $(0.38) Misses $(0.20) Estimate, Sales $13.200M Miss $14.440M Estimate
FocalTherics (NASDAQ:FOCL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.20) by 90 percent. This is a 123.53 percent decrease over losses of $(0.17) per share from the